Clinical Trial ProgressPositive safety data from Cohort 1 of the CHASE trial was reported, allowing the trial to advance to the next phase.
Financial PerformanceNet loss of $38.5M in 2024 was less than the estimated loss, indicating better-than-expected financial performance.
Market OpportunityThere is no FDA-approved drug with a broad indication for all underlying etiologies of PCED, which highlights the potential market opportunity for KPI-012.